Tzield MOA and Dosing

Tzield is the first and only disease modifying immunotherapy developed for aT1D that treats the underlying cause of the disease by preserving beta-cell function.^1-3

Mechanism of Action

Prescription and Dosing

Unlike other chronic diabetes therapies, Tzield is a finite course of treatment. For Stage 2, 
Tzield is administered through a single cycle of 14-day IV infusion.⁵ 

• Teplizumab is administered by IV (over a minimum of 30 minutes) once daily for 14 consecutive days
• The recommended dose for adults and pediatric patients aged ≥8 years is based on BSA according to the following:
  • Two doses should not be administered on the same day
  • If a planned teplizumab infusion is missed, resume dosing by administering all remaining doses on consecutive days to complete the 14-day treatment course